Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$4.57 CAD
Change Today +0.12 / 2.70%
Volume 2.2K
QLT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:39 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

887 Great Northern Way

Suite 250

Vancouver, BC V5T 4T5

Canada

Phone: 604-707-7000

Fax: 604-707-7001

QLT Inc., a biotechnology company, engages in the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians worldwide. Products in Development QLT091001 – Synthetic Retinoid Program The company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. The company is developing QLT091001 for the treatment of leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). In 2014, the company met with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including an end-of-phase II meeting with the FDA, to progress QLT091001 for the treatment of certain inherited retinal diseases toward pivotal trials. The company also conducted a Phase IIa trial of QLT091001 for the treatment of impaired dark adaptation to investigate the safety and efficacy of the drug in a larger patient population. The company has also conducted a Phase 1b study in five RP patients with autosomal dominant mutation in retinal pigment epithelium protein 65 (RPE65). QLT091001 has received orphan drug designations from the FDA and the EMA for the treatment of certain indications under evaluation. The company has a co-development agreement with Retinagenix LLC (Retinagenix), pursuant to which the company obtained an exclusive, worldwide license and sub-license under certain intellectual property rights owned by Retinagenix or licensed to Retinagenix by the University of Washington, related to the synthetic retinoid compound under development, and are responsible for using commercially reasonable and diligent efforts to develop and commercialize, in certain major markets and other markets as the company reasonably determines, one or more products covered by the licensed rights or developed using such licensed rights for use in diagnosing, treating or preventing certain human diseases and conditions. QLT091001 has also been granted two Fast Track designations by the FDA for the treatment of the lecithin:retinol acyltransferase and RPE65 genetic mutations in both LCA and autosomal recessive RP. Government Regulation The company and its contract manufacturers are subject to the FDA’s current Good Manufacturing Practices regulations and other rules and regulations prescribed by regulatory authorities outside the U.S. The research and development, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of the company’s products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries. The U.S. Food, Drug and Cosmetic Act and its regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, approval, distribution, export and import, advertising and promotion of the company’s products. Research and Development During the year ended December 31, 2014, the company’s total company-sponsored research and development expenses were $13.8 million. History QLT Inc. was formed in 1981 under the laws of the province of British Columbia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:CN C$4.57 CAD +0.12

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies
 

Industry Analysis

QLT

Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit www.qltinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.